Replies to post #44475 on Relief Therapeutics Holding AG (RLFTF)

[rollup]

You forgot the most important point for me in the NIH publication....

Conclusions: The primary end point did not reach statistical significance, indicating that there was no difference between Aviptadil versus placebo. However, Aviptadil improves the likelihood of survival from respiratory failure at day 60 in critical COVID-19 across all sites of care. Given the absence of drug-related serious adverse events and acceptable safety profile, we believe the benefit versus risk for the use of Aviptadil is favorable for patient treatment.

insert-text-here